Physician profile
Amy L Nance
NPI 1407032097
$4,128.46
in general payments reported to CMS, 2019-2025
54 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $136 · 2021: $147 · 2022: $519 · 2023: $641 · 2024: $770 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,841 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,840.93 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $395.34 | 2020-2023 | Tukysa, Adcetris |
| Janssen Biotech, INC. | $356.56 | 2019-2025 | Darzalex, Erleada, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $268.94 | 2019-2025 | Opdivo, Krazati |
| Pfizer INC. | $259.57 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $221.18 | 2021-2025 | Enhertu, Imfinzi |
| Genzyme Corporation | $204.52 | 2019-2025 | |
| Daiichi Sankyo INC. | $191.44 | 2020-2025 | Enhertu, Datroway, Vanflyta |
| Novartis Pharmaceuticals Corporation | $167.26 | 2022-2025 | |
| Celgene Corporation | $162.97 | 2019-2025 | Opdualag, Opdivo, Pomalyst |
| Astellas Pharma US INC | $145.68 | 2022-2025 | Padcev, Xtandi, Xospata |
| Tesaro, INC. | $136.94 | 2019 | |
| Amgen INC. | $111.30 | 2019-2022 | |
| Abbvie INC. | $103.66 | 2023-2025 | |
| Emd Serono, INC. | $100.72 | 2024-2025 | |
| Gilead Sciences, INC. | $96.22 | 2021-2025 | Trodelvy |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $94.12 | 2019-2025 | Vpriv, Iclusig |
| Ipsen Biopharmaceuticals, INC | $83.42 | 2019-2023 | Somatuline Depot, Onivyde |
| Merck Sharp & Dohme LLC | $70.18 | 2019-2025 | Keytruda |
| Taiho Oncology, INC. | $65.67 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $58.20 | 2024-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $48.15 | 2021-2023 | |
| Csl Behring | $43.05 | 2022-2025 | Afstyla, Idelvion |
| Kyowa Kirin, INC. | $41.83 | 2023-2025 | Poteligeo |
| Octapharma USA, INC. | $41.57 | 2024-2025 | Octagam Immune Globulin (Human) |
| Eisai INC. | $39.53 | 2022-2023 | |
| Tersera Therapeutics LLC | $39.33 | 2025 | Zoladex |
| Karyopharm Therapeutics INC. | $36.94 | 2023-2025 | Xpovio |
| Beigene USA, INC. | $31.91 | 2022-2023 | Brukinsa |
| Genmab U.S., INC. | $31.86 | 2023 | Epkinly |
| Servier Pharmaceuticals LLC | $30.11 | 2022-2024 | |
| Incyte Corporation | $30.00 | 2022-2025 | Jakafi |
| Apellis Pharmaceuticals, INC. | $28.05 | 2023 | Empaveli |
| Mirati Therapeutics, INC. | $27.03 | 2023-2024 | Krazati |
| Springworks Therapeutics, INC. | $24.76 | 2025 | Ogsiveo |
| Tempus Ai, INC | $24.52 | 2025 | Xt Cdx |
| Pharmaessentia USA Corporation | $24.45 | 2025 | Besremi |
| Genentech USA, INC. | $22.22 | 2022 | |
| Dendreon Pharmaceuticals LLC | $20.73 | 2025 | Provenge |
| Exelixis INC. | $20.71 | 2024 | Cabometyx |
| Novocure INC. | $20.40 | 2025 | Optune Gio |
| Cumberland Pharmaceuticals, INC. | $19.86 | 2025 | Sancuso |
| Puma Biotechnology, INC. | $19.62 | 2020 | |
| Recordati_rare_diseases_inc. | $18.03 | 2025 | Enjaymo |
| Aurobindo Pharma USA, INC. | $17.87 | 2019 | |
| Array Biopharma INC | $16.88 | 2023 | Lorbrena, Braftovi, Mektovi |
| Fennec Pharmaceuticals, INC. | $16.67 | 2025 | Fyarro |
| Shire North American Group INC | $16.56 | 2019 | |
| Cti Biopharma Corp. | $15.87 | 2023 | Vonjo |
| Amag Pharmaceuticals, INC. | $15.87 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.19 | 2022 | |
| Geron Corporation | $15.11 | 2025 | Rytelo |
| Rigel Pharmaceuticals, INC. | $12.76 | 2019 | |
| Biocartis US, INC | $6.55 | 2023 | Idylla |
| Veracyte, INC. | $0.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Nance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.